Lisata Therapeutics Inc. has announced positive preliminary results from Cohort B of the ASCEND Phase 2b trial. This trial, sponsored by the Australasian Gastro-Intestinal Trials Group and conducted in collaboration with the NHMRC Clinical Trials Centre at the University of Sydney, evaluates the efficacy of certepetide in combination with standard-of-care chemotherapy for metastatic pancreatic cancer. The Cohort B data supports earlier findings from Cohort A, indicating that certepetide demonstrates a treatment effect and maintains an attractive safety profile. The results show a positive signal in progression-free survival and objective response rate in the certepetide-treated group compared to placebo. The full study data from both cohorts is anticipated later this year, with Dr. Andrew Dean scheduled to present the findings at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.